Original Publication Date: 1 September, 2017
Publication / Source: Immunotherapy 9(11)
Authors: Saleh K, Khalife-saleh N & Kourie HR
Immune checkpoint inhibitors (ICI) are changing the treatment of solid and hematologic malignancies and becoming an integral part of the management of cancer patients. Ipilimumab, a CTLA-4 inhibitor, was associated with significant survival benefit in metastatic melanoma . In addition, PD-1 and PD-L1 inhibitors such as nivolumab, pembrolizumab and atezolizumab showed remarkable clinical responses in multiple cancer types ranging from 20 to 30% when used in monotherapy. These agents are approved by the US FDA in the management of various tumor
Click here to view the full article in Immunotherapy.